Table 2.

Completed, ongoing, and planned studies of rivipansel, SelG1, regadenoson, and NKTT120

Completed, ongoing, and planned studies of rivipansel, SelG1, regadenoson, and NKTT120

RCT indicates randomized controlled trial; and SAE, serious adverse event.

* Dose schedule noted for dose-seeking studies is final dose achieved.

† The first 31 subjects received a 20 mg/kg loading dose and then 10 mg/kg every 12 hours.

‡ Adult dose listed in table. Pediatric dose will be 40 mg/kg load followed by 20 mg/kg every 12 hours up to 15 doses.

Close Modal

or Create an Account

Close Modal
Close Modal